Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Phyllis E. Kozarsky is active.

Publication


Featured researches published by Phyllis E. Kozarsky.


Clinical Infectious Diseases | 2006

The Practice of Travel Medicine: Guidelines by the Infectious Diseases Society of America

David R. Hill; Charles D. Ericsson; Richard D. Pearson; Jay S. Keystone; David O. Freedman; Phyllis E. Kozarsky; Herbert L. DuPont; Frank J. Bia; Philip R. Fischer; Edward T. Ryan

David R. Hill, Charles D. Ericsson, Richard D. Pearson, Jay S. Keystone, David O. Freedman, Phyllis E. Kozarsky, Herbert L. DuPont, Frank J. Bia, Philip R. Fischer, and Edward T. Ryan National Travel Health Network and Centre and Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, England; Department of Medicine, University of Toronto, and Center for Travel and Tropical Medicine, Toronto General Hospital, Toronto, Ontario, Canada; Department of Internal Medicine, Clinical Infectious Diseases, University of Texas Medical School at Houston, Department of Internal Medicine, St. Luke’s Hospital, and Center for Infectious Diseases, University of Texas at Houston School of Public Health, and Department of Medicine, Baylor College of Medicine, Houston, Texas; Departments of Medicine and Pathology, Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia; Departments of Medicine and Epidemiology, Division of Geographic Medicine, University of Alabama at Birmingham, Birmingham; Department of Medicine, Infectious Diseases, Emory University School of Medicine, and 16 Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, Georgia; Department of Medicine and Laboratory Medicine, Yale Medical School, New Haven, Connecticut; Department of Pediatrics, Division of General Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine, and Mayo Eugenio Litta Children’s Hospital, Mayo Clinic, Rochester, Minnesota; and Department of Medicine, Division of Infectious Diseases, Harvard Medical School, Harvard School of Public Health, and Tropical and Geographic Medicine Center, Massachusetts General Hospital, Boston, Massachusetts


Vaccine | 2008

Adverse event reports following yellow fever vaccination.

Nicole P. Lindsey; Betsy A. Schroeder; Elaine R. Miller; M. Miles Braun; Alison F. Hinckley; Nina Marano; Barbara A. Slade; Elizabeth D. Barnett; Gary W. Brunette; Katherine Horan; J. Erin Staples; Phyllis E. Kozarsky; Edward B. Hayes

Yellow fever (YF) vaccine has been used for prevention of YF since 1937 with over 500 million doses administered. However, rare reports of severe adverse events following vaccination have raised concerns about the vaccines safety. We reviewed reports of adverse events following YF vaccination reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from 2000 to 2006. We used estimates of age and sex distribution of administered doses obtained from a 2006 survey of authorized vaccine providers to calculate age- and sex-specific reporting rates of all serious adverse events (SAE), anaphylaxis, YF vaccine-associated neurotropic disease, and YF vaccine-associated viscerotropic disease. Reporting rates of SAEs were substantially higher in males and in persons aged > or =60 years. These findings reinforce the generally acceptable safety profile of YF vaccine, but highlight the importance of physician and traveler education regarding the risks and benefits of YF vaccination, particularly for travelers > or =60 years of age. Vaccination should be limited to persons traveling to areas where the risk of YF is expected to exceed the risk of serious adverse events after vaccination, or if not medically contraindicated, where national regulations require proof of vaccination to prevent introduction of YF.


Emerging Infectious Diseases | 2002

Clinical Issues in the Prophylaxis, Diagnosis, and Treatment of Anthrax

David M. Bell; Phyllis E. Kozarsky; David S. Stephens

On November 18, 2001, a meeting was held at the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, to discuss the prophylaxis, diagnosis, and treatment of anthrax. Participants included clinicians and health department personnel from areas where anthrax cases were identified, infectious disease experts, representatives of professional societies, and experts from federal agencies. A patient recovering from inhalational anthrax also described her illness. The following is a summary of the presentations and discussion.


Infectious Disease Clinics of North America | 1998

EMERGING INFECTIOUS DISEASES AND TRAVEL MEDICINE

Stephen M. Ostroff; Phyllis E. Kozarsky

International movement of individuals, populations, and products is one of the major factors associated with the emergence and reemergence of infectious diseases as the pace of global travel and commerce increases rapidly. Travel can be associated with disease emergence because (1) the disease arises in an area of heavy tourism, (2) tourists may be at heightened risk because of their activities, or (3) because they can act as vectors to transport the agent to new areas. Examples of recently recognized diseases with relationship to travel include HIV, Legionnaires disease, cyclosporiasis, Vibrio cholerae O139 Bengal, hantavirus, and variant Creutzfeldt-Jacob disease. Reemerging diseases include dengue fever, malaria, cholera, schistosomiasis, leptospirosis, and viral hemorrhagic fevers. In addition, tuberculosis, drug-resistant shigellosis, and cholera have been major concerns in refugee and migrant populations. Because of the unique role of travel in emerging infections, efforts are underway to address this factor by agencies such as the CDC, WHO, the International Society of Travel Medicine, and the travel industry.


Journal of Travel Medicine | 2009

Pretravel Health Preparation Among US Residents Traveling to India to VFRs: Importance of Ethnicity in Defining VFRs

Henry C. Baggett; Susan Graham; Phyllis E. Kozarsky; Nancy Gallagher; Sena Blumensaadt; John Bateman; Paul J. Edelson; Paul M. Arguin; Stefanie Steele; Michelle Russell; Christie Reed

BACKGROUND International travelers visiting friends and relatives (VFRs) in lower income countries experience high rates of travel-related infections. We examined demographic characteristics and pretravel preparation practices among US residents traveling to India to determine factors that may contribute to higher infection rates and that would allow for improved prevention strategies. METHODS A cross-sectional study was conducted among US residents traveling to India in departure areas for flights to India at three US international airports during August 2005. Eligible travelers were US residents going to India who were English speaking and >or=18 years. Self-administered questionnaires were used to assess knowledge of and compliance with pretravel health recommendations. RESULTS Of 1,574 eligible travelers, 1,302 (83%) participated; 60% were male and the median age was 37. Eighty-five percent were of South Asian/Indian ethnicity and 76% reported VFR as the primary reason for travel. More than 90% of VFRs had at least a college education and only 6% cited financial barriers as reasons for not obtaining travel health services. VFRs were less likely than non-VFR travelers to seek pretravel health advice, to be protected against hepatitis A or typhoid fever, and less likely to be taking appropriate antimalarial chemoprophylaxis. However, when stratified by ethnicity, travelers of South Asian ethnicity were less likely than other travelers to adhere to pretravel health recommendations, regardless of VFR status. CONCLUSIONS Similar to previous studies, VFR status was associated with pretravel health practices that leave travelers at risk for important infectious diseases. This association differed by ethnicity, which may also be an important marker of nonadherence to pretravel health recommendations. These findings have important implications for identifying at-risk travelers and properly targeting prevention messages.


Journal of Travel Medicine | 2006

Schistosome infection among river rafters on Omo River, Ethiopia.

Eli Schwartz; Phyllis E. Kozarsky; Marianna Wilson; Martin S. Cetron

BACKGROUND Adventure trips to Africa have become more frequent, and rafting on some of the great rivers has become almost commonplace. We describe three rafting trips on the Omo River in Ethiopia, after which most of the participants were diagnosed with schistosomiasis. METHODS After index cases from the three groups came to medical attention, active surveillance detected outbreaks of illness in a group of American travelers (n = 18 ) in 1993 and in two groups of Israeli travelers in 1997 (n = 26). RESULTS Of 44 travelers, 37 were screened and 28 (76%) were infected, all with Schistosoma mansoni. Among the infected patients, 16 of 28 (57%) were symptomatic, the most frequent manifestation being fever, which occurred in 14 of 25 (56%); cough occurred in 6 of 18 (33%). Diagnosis was based on FAST-enzyme-linked immunosorbent assay, with confirmation by immunoblot. Other rafting trips on the Omo River sponsored by the same tour companies did not result in symptomatic infection. Investigation of the rafting itineraries suggested the route may have been altered from the usual for these three groups, exposing them to a part of the river that is wider, slower moving, and more densely populated. CONCLUSIONS Schistosomiasis should be considered in febrile patients following rafting trips in schistosome-endemic areas. As asymptomatic schistosomiasis in travelers is also common (43% in this series), all travelers exposed to freshwater in endemic areas should be encouraged to undergo serologic screening.


Clinical Infectious Diseases | 2001

Internet and Computer-Based Resources for Travel Medicine Practitioners

Victor L. Yu; Jay S. Keystone; Phyllis E. Kozarsky; David O. Freedman

The field of travel medicine is concerned primarily with ways to maintain the health of international travelers. Remaining current in this area requires up-to-date knowledge of global infectious diseases, patterns of drug resistance, advances in preventive measures, and public health regulations pertaining to the crossing of international borders. This review of off-line commercial databases and Internet sources will assist infectious disease consultants in accessing current reliable travel health information. Of the North American pretravel off-line databases, TRAVAX (United States) and The Medical Letter are the most comprehensive, whereas the Global Infectious Disease and Epidemiology Network is extraordinary in its provision of global infectious disease epidemiology for posttravel assessment. A total of 65 Web sites are listed within 9 categories, covering such areas as authoritative government travel health recommendations, commercially-oriented sites, and travel medicine listserv discussion groups. Even among reputable Web sites, contradictory information may be found that demands careful consideration by the clinician and by the traveling public.


Annals of Internal Medicine | 2017

Travel-associated Zika virus disease acquired in the americas through February 2016: A GeoSentinel analysis

Davidson H. Hamer; Kira A. Barbre; Lin H. Chen; Martin P. Grobusch; Patricia Schlagenhauf; Abraham Goorhuis; Perry J. J. van Genderen; Israel Molina; Hilmir Asgeirsson; Phyllis E. Kozarsky; Eric Caumes; Stefan Hagmann; Frank P. Mockenhaupt; Gilles Eperon; Elizabeth D. Barnett; Emmanuel Bottieau; Andrea K. Boggild; Philippe Gautret; Noreen A. Hynes; Susan Kuhn; R. Ryan Lash; Karin Leder; Michael Libman; D. Malvy; Cecilia Perret; Camilla Rothe; Eli Schwartz; Annelies Wilder-Smith; Martin S. Cetron; Douglas H. Esposito

Background Zika virus has spread rapidly in the Americas and has been imported into many nonendemic countries by travelers. Objective To describe clinical manifestations and epidemiology of Zika virus disease in travelers exposed in the Americas. Design Descriptive, using GeoSentinel records. Setting 63 travel and tropical medicine clinics in 30 countries. Patients Ill returned travelers with a confirmed, probable, or clinically suspected diagnosis of Zika virus disease seen between January 2013 and 29 February 2016. Measurements Frequencies of demographic, trip, and clinical characteristics and complications. Results Starting in May 2015, 93 cases of Zika virus disease were reported. Common symptoms included exanthema (88%), fever (76%), and arthralgia (72%). Fifty-nine percent of patients were exposed in South America; 71% were diagnosed in Europe. Case status was established most commonly by polymerase chain reaction (PCR) testing of blood and less often by PCR testing of other body fluids or serology and plaque-reduction neutralization testing. Two patients developed Guillain-Barré syndrome, and 3 of 4 pregnancies had adverse outcomes (microcephaly, major fetal neurologic abnormalities, and intrauterine fetal death). Limitation Surveillance data collected by specialized clinics may not be representative of all ill returned travelers, and denominator data are unavailable. Conclusion These surveillance data help characterize the clinical manifestations and adverse outcomes of Zika virus disease among travelers infected in the Americas and show a need for global standardization of diagnostic testing. The serious fetal complications observed in this study highlight the importance of travel advisories and prevention measures for pregnant women and their partners. Travelers are sentinels for global Zika virus circulation and may facilitate further transmission. Primary Funding Source Centers for Disease Control and Prevention, International Society of Travel Medicine, and Public Health Agency of Canada.


The New England Journal of Medicine | 2016

Medical Considerations before International Travel

David O. Freedman; Lin H. Chen; Phyllis E. Kozarsky

The scope of illnesses that may befall international travelers is broad. A guide to preparing for the preventable causes of illness is provided. Physicians may find it useful in counseling their patients who travel internationally.


Emerging Infectious Diseases | 2014

Regional Variation in Travel-related Illness acquired in Africa, March 1997-May 2011

Marc Mendelson; Pauline V. Han; Peter Vincent; Frank von Sonnenburg; Jakob P. Cramer; Louis Loutan; Kevin C. Kain; Philippe Parola; Stefan Hagmann; Effrossyni Gkrania-Klotsas; Mark J. Sotir; Patricia Schlagenhauf; Rahul Anand; Hilmir Asgeirsson; Elizabeth D. Barnett; Sarah Borwein; Gerd D. Burchard; John D. Cahill; Daniel Campion; Francesco Castelli; Eric Caumes; Lin H. Chen; Bradley A. Connor; Christina M. Coyle; Jane Eason; Cécile Ficko; Vanessa Field; David O. Freedman; Abram Goorhuis; Martin P. Grobusch

To understand geographic variation in travel-related illness acquired in distinct African regions, we used the GeoSentinel Surveillance Network database to analyze records for 16,893 ill travelers returning from Africa over a 14-year period. Travelers to northern Africa most commonly reported gastrointestinal illnesses and dog bites. Febrile illnesses were more common in travelers returning from sub-Saharan countries. Eleven travelers died, 9 of malaria; these deaths occurred mainly among male business travelers to sub-Saharan Africa. The profile of illness varied substantially by region: malaria predominated in travelers returning from Central and Western Africa; schistosomiasis, strongyloidiasis, and dengue from Eastern and Western Africa; and loaisis from Central Africa. There were few reports of vaccine-preventable infections, HIV infection, and tuberculosis. Geographic profiling of illness acquired during travel to Africa guides targeted pretravel advice, expedites diagnosis in ill returning travelers, and may influence destination choices in tourism.

Collaboration


Dive into the Phyllis E. Kozarsky's collaboration.

Top Co-Authors

Avatar

David O. Freedman

University of Alabama at Birmingham

View shared research outputs
Top Co-Authors

Avatar

Mark J. Sotir

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Douglas H. Esposito

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Martin S. Cetron

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Gary W. Brunette

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bradley A. Connor

NewYork–Presbyterian Hospital

View shared research outputs
Top Co-Authors

Avatar

Stefan Hagmann

Bronx-Lebanon Hospital Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge